Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 33, Issue 7, 2004, Pages 703-707

  Endo, T ^a   Sato, N ^b   Mogi, Y ^c   Koizumi, K ^a   Nishio, M ^a   Fujimoto, K ^a   Sakai, T ^a   Kumano, K ^a   Obara, M ^a   Ikeda, H ^c   Koike, T ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c JAPANESE RED CROSS SOCIETY   (Japan)

Author keywords

CHOP; Mobilization; Peripheral blood stem cell (PBSC); Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CD20 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; RANIMUSTINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CELL KINETICS; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EYELID EDEMA; FEMALE; FEVER; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKAPHERESIS; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; TARGET CELL; THROAT DISEASE; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE REARRANGEMENT; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; KINETICS; LEUKAPHERESIS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; TRANSPLANTATION CONDITIONING; VINCRISTINE;

EID: 16544380273     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704413     Document Type: Article

References (20)

1. Shipp MA, Abeloff MD, Antman KH et al. International consensus on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423-429.
2. Horning SJ. High-dose therapy and transplantation for low-grade lymphoma. Hematol Oncol Clin North Am 1997; 11: 919-935.
3. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
4. Freedman AS, Gribben JG, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
5. Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-1533.
6. + peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol 1997; 15: 2288-2295.
7. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274.
8. Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229-235.
9. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
10. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729-735.
11. Flohr T, Hess G, Kolbe K et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 2002; 29: 769-775.
12. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
13. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9: 211-219.
14. Sawada K, Sato N, Kohno M et al. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen. Leuk Lymphoma 1995; 20: 103-109.
15. Takano H, Sawada K, Sato N et al. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1996; 21: 473-478.
16. + cells. Blood 1993; 82: 3600-3609.
17. Clarke BJ, Housman D. Characterization of an erythroid precursor cell of high proliferative capacity in normal human peripheral blood. Proc Natl Acad Sci USA 1977; 74: 1105-1109.
18. Tarumi T, Sawada K, Koizumi K et al. A pilot study of a response oriented chemotherapeutic regimen combined with autologous peripheral blood progenitor cell transplantation in aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 34: 361-371.
19. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 115-122.
20. Friedman J, Lazarus HM, Koc ON. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulaied PBPC transplantation. Bone Marrow Transplant 2000; 26: 831-836.